Clinical Trials Logo

Bone Diseases, Metabolic clinical trials

View clinical trials related to Bone Diseases, Metabolic.

Filter by:

NCT ID: NCT04702516 Recruiting - Osteopenia Clinical Trials

The Effect of Semaglutide on Bone Turnover in Patients With Increased Risk of Bone Fracture

Start date: March 24, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The hypothesis for this study is that the GLP-1Ra Semaglutide has a positive effect on the balance between build-up and degradation as well as the strength of the bones in men and women aged 40-85 years at increased risk of bone fractures. Treatment involves injection of Semaglutide 1.34 mg/ml once a week or corresponding volume of placebo once a week for 52 weeks. The effect will be measured by bone markers in blood samples, bone scans, bone tissue tests (bone biopsy), and direct bone strength measured by microindentation at the start and end of the study.

NCT ID: NCT04669782 Recruiting - Osteoporosis Clinical Trials

Effect of Vitamin K Supplementation on Circulating Levels of Osteocalcin on the Bone Metabolism and Aging

OstMARK
Start date: November 24, 2020
Phase: N/A
Study type: Interventional

This is an interventional study on nutraceuticals. It is a randomized controlled, open-label, prospective, single-center study that involves the enrollment of 82 patients with osteoporosis and 41 subjects without osteoporosis. The hypothesis the decarboxylated form of Osteocalcin (OC), called GluOC, represents a clinically useful marker for monitoring the effects of supplementation with vitamin K in association with anabolic treatment with teriparatide will be analyzed not only on bone but also on skeletal muscle and energy metabolism in patients with severe osteoporosis.

NCT ID: NCT04528446 Recruiting - Bone Fracture Clinical Trials

The Impact of Glomerular Disorders on Bone Quality and Strength

BoneGN
Start date: June 14, 2019
Phase:
Study type: Observational

The primary objectives of this study are to: (1) determine the impact of glomerular disease on bone strength and (2) investigate the pathophysiologic underpinnings of impaired bone strength in glomerular disease.

NCT ID: NCT04518722 Recruiting - Asthma Clinical Trials

CT-Based Changes in Bone and Marrow Among Patients on Oral Steroids

Start date: December 1, 2020
Phase:
Study type: Observational

The goal of this study is to assess the feasibility of emerging CT-based tools to measure changes in central and peripheral bone density, micro-structure, and marrow adipose tissue (MAT) among patients treated with oral steroids.

NCT ID: NCT04385355 Recruiting - Clinical trials for Peri-implant Bone Loss

Influence of the Design of the Transmucosal Abutment on the Periimplant Bone Level

Start date: October 1, 2024
Phase: N/A
Study type: Interventional

The objective of this study is to evaluate the radiographic changes on the marginal peri-implant bone level on bone level implants with a narrower transmucosal abutment, in comparison to the conventional abutment, both of 3mm height

NCT ID: NCT04328051 Recruiting - Clinical trials for Bacterial Infections

Influence of the Implant-prosthetic Connection in the Marginal Bone Loss and Bacterial Leakage

Start date: June 13, 2018
Phase: N/A
Study type: Interventional

This study consists in a double-blinded randomized controlled trial which objective is to assess the effect of the implant-abutment connection type -external hexagon, internal hexagon and conical connection- in the periimplant marginal bone loss in vertical side and the bacterial leakage 12 months after prosthesis placement.

NCT ID: NCT04079868 Recruiting - Osteoporosis Clinical Trials

Models of Primary Osteoporosis Screening in Male Veterans

MOPS
Start date: August 30, 2019
Phase: N/A
Study type: Interventional

Models of Osteoporosis Screening in Male Veterans aims to test 1 distinct care model of primary osteoporosis screening in men within the VA healthcare setting. All care models deliver VA recommended osteoporosis screening and treatment to high-risk Veterans by appropriate Durham VA clinical staff. The MOPS project will evaluate patient, provider and facility outcomes to determine the effectiveness of each intervention.

NCT ID: NCT03916289 Recruiting - Osteoporosis Clinical Trials

A Tiered Management System of Osteoporosis in China

Start date: November 1, 2018
Phase:
Study type: Observational [Patient Registry]

There is a management gap in China. This study aims to establish a tiered management system of osteoporosis for Chinese patients. Including: 1. Developing a national hierarchical health management network platform for middle-aged and elderly osteoporosis patients. With this platform, the data of medical records, laboratory results would be shared between medical institutions. And primary hospitals can refer the patients to the nearest medical centre for advanced auxiliary examinations and diagnosis. 2. Establishing a muti-level hospital collaboration, doctor-patient interaction management model of osteoporosis. 3. To explore and establish a early warning and screening pathways for osteoporosis.

NCT ID: NCT03889717 Recruiting - Clinical trials for Osteopenia of Prematurity

Comparison of Two Different Doses of Vitamin D in Preterm Infants

Start date: April 16, 2019
Phase: N/A
Study type: Interventional

randomized clinical trial comparing two different doses of vitamin d supplementation in preterm infants

NCT ID: NCT03549312 Recruiting - HIV/AIDS Clinical Trials

Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplification of HIV Therapy With Biktarvy in Patients With HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy

Start date: February 1, 2018
Phase: Phase 4
Study type: Interventional

The study hypothesis is to determine the feasibility of switching HIV-HCV co-infected patients receiving methadone or buprenorphine/naloxone as opioid substitution therapy with suppressed HIV RNA viral load on current antiretroviral therapy to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF, Genvoya™) followed by 12 weeks of HCV antiviral therapy with sofosbuvir/velpatasvir (SOF/VEL, Epclusa™), followed then by switch to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF, Biktarvy™) for an additional 48 weeks.